Introduction
Pulmonary thromboembolism is the most common cause of mortality in hospitalized patients, accounting for ~60% of in-hospital mortality at present (1) . A massive pulmonary embolism can lead to cardiac arrest (CA) in 41% of patients, with a mortality ranging from 65-95% (2) . Pneumocyte apoptosis is the most significant pathological observation in the lung following an incidence of acute pulmonary embolism (APE). Li et al (3) have reported the presence of apoptotic cells as well as decreased expression of the anti-apoptotic proteins B-cell lymphoma (Bcl)-2 and Bcl-extra large in lung tissues following an APE, as compared with the controls. This cellular damage in the lung might be responsible for a subsequent severe lung dysfunction (4, 5) .
The renin-angiotensin system serves an important role in the regulation of apoptosis in alveolar epithelial cells (AECs). Recently, several research groups have identified a novel pathway called angiotensin-converting enzyme2 (ACE2)-angiotensin (Ang)-1-7-Mas1 proto-oncogene, G protein-coupled receptor (Mas) axis that acts contrary to the classic ACE-Ang II-Ang II type 1 (AT1) receptor axis (6) (7) (8) (9) . The pro-apoptotic role of the classic ACE axis in AECs in response to Fas activation has been well studied (6) . Ang II is known to chemically induce apoptosis in AECs (7). Wang et al (8) demonstrated that ACE2 can attenuate bleomycin-induced lung fibrosis by inhibiting the apoptosis in pulmonary epithelial cells. Similarly, Ji et al (9) demonstrated that ACE2 inhibits apoptosis in pulmonary endothelial cells during acute lung injury. Our previous study demonstrated a reduction in post-resuscitation pulmonary vascular resistance following captopril treatment, which activated the ACE2-Ang-(1-7)-Mas axis (10) . However, the role of ACE2/ACE balance on pneumocyte apoptosis in massive APE-CA remains unclear. Thus, in the present study, it was aimed to examine the correlation between ACE2/ACE balance and apoptotic factors in the lung and to investigate the effect of captopril on pulmonary apoptosis in an APE-CA pig model. A7-F Swan-Ganz catheter (Edwards Lifesciences Corp., Irvine, CA, USA) was flowed into the pulmonary artery from the right external jugular vein to monitor mean pulmonary artery pressure. An arterial catheter was inserted into the left femoral artery to measure aortic pressure. A triple lumen central venous catheter was inserted into the left femoral vein to monitor central venous pressure. A large-bore catheter (internal diameter 1.0 cm) was inserted into the left external jugular vein with its tip touching the opening of the pulmonary artery for infusion of blood clots, under the guidance of a computed tomography. Normal saline and 5% glucose saline (8 ml/kg/h) were infused via the right femoral vein to compensate for the fluid loss and to maintain a constant central venous pressure (5-12 mmHg). Electrocardiographic and hemodynamic parameters were also monitored (M8001A; Philips Medizin Systeme Böblingen GmbH, Böblingen, Germany).
Experimental protocol. An APE-CA model was established as described previously (10) . Briefly, 100 ml of blood was drawn out from the femoral vein and allowed to self-coagulate at room temperature (2-3 h). The clots (10-15 ml) were cut into pieces (1.5x1x1 cm) and were suspended in normal saline in a large catheter tip syringe. Subsequently, the clot pieces were injected into the left external jugular vein >2 min until a mean arterial pressure <30 mmHg was reached, yielding a porcine model of APE-CA (11) . To establish an APE-return of spontaneous circulation (ROSC) model, urokinase (15,000 U/kg) was infused into the pulmonary artery using a Swan-Ganz catheter and cardiopulmonary resuscitation was immediately initiated (following the 2010 American Heart Association guidelines) (12) . ROSC was verified based on a systolic blood pressure >50 mmHg for 10 min (13) . If ROSC was not restored within 30 min, the animals were considered dead.
Pigs (n=29) were randomly assigned into four groups. Group 1 (control group, n=5) was injected with 10 ml potassium chloride (15%) intravenously followed by a bolus of propofol (100 mg) at 6 h following experimental preparation. All animals in this group were sacrificed due to ventricular fibrillation. Group 2 (APE-CA group, n=5) underwent the procedure outlined above. All animals in this group were sacrificed due to ventricular fibrillation or electromechanical diastolic arrest. Nineteen animals received a thrombus injection as described above for the establishment of APE-ROSC model. Ten out of nineteen animals were successfully resuscitated and were randomly assigned into two subgroups: ROSC-Cap (n=5), receiving an injection of captopril (22.22 mg/kg; cat. no. C8856-1G, Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) 30 min after ROSC, and ROSC-SA (saline; n=5), receiving an injection of equivalent normal saline 30 min after ROSC. Subsequently, all animals in both subgroups (~6 h following ROSC) were euthanized with an intravenous injection of 10 ml potassium chloride (15%) following a bolus of 100 mg propofol. Lung tissue was isolated and was immediately frozen in liquid nitrogen and stored at -80˚C until further analysis.
Histological evaluation. Lung tissues were fixed in 10% buffered formalin for 48 h, dehydrated with alcohol solutions of gradient concentration (100, 95, 80 and 75%), sliced at 4 µm thickness, and sections were stained with hematoxylin (15 sec)-eosin (30 sec) and dried 20 min at 55˚C. The lung pathological changes were observed under a light Nikon Eclipse Ci-Emicroscope (Olympus Corporation, Tokyo, Japan) under the low (10x10) and high magnification (10x40).
Western blot analysis. Each lung tissue sample (20 mg) was chopped into fragments and homogenized in 200 µl radioimmunoprecipitation lysis buffer (Roche Diagnostics, Basel, Switzerland). Tissue lysates were centrifuged (13,000 x g, 20 min, 4˚C) and immediately harvested and stored at -80˚C until further use. A bicinchoninic acid protein assay kit (Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used to measure protein concentrations in the supernatant. The tissue lysate was mixed with the same volume of 5X sodium lauryl sulfate (SDS) buffer [2.5 ml 0.5 mol/l Tris-HCl (pH 6.8), 0.39 g DTT, 0.5 g SDS, 0.025 g bromophenol blue, and 2.5 ml glycerol] to obtain a mixture at a final concentration of 3 µg/µl. The homogenates were heated at 95˚C for 5 min. Using 8, 10 and 15% SDS-polyacrylamide gels, total proteins (40 µg) were separated and transferred onto a 0.45-µm polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA) for 40-100 min. Following blocking with 5% nonfat dry milk for 1 h at room temperature, the membranes were incubated, first, with 1:500 dilution ofACE2 (cat. Immunohistochemical staining. For the detection of cleaved caspase-3 in lung tissues, immunohistochemical staining was used. Lung tissues were fixed in 10% buffered formalin for 48 h at room temperature, dehydrated with alcohol solutions of gradient concentration (100, 95, 80 and 75%), sliced at 4 µm thickness, and embedded in paraffin. The sections were placed in histosol for the removal of paraffin, rehydrated in graded ethanol, and blocked in 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA, Darmstadt, USA) for 4 h. Slides were incubated with cleaved-caspase3 antibody (1:1,000 dilution; cat. no. 9664s; CST Biological Reagents Co., Ltd., Shanghai, China) overnight at 4˚C. Sections incubated in normal rabbit serum served as negative controls. Following primary antibody incubation, sections were washed with phosphate buffer saline and were incubated with avidin-biotin peroxidase-conjugated secondary antibody (1:200; cat. no. PK-4001; ZSGB-Biotechnology; OriGene Technologies, Inc., Beijing, China) for 2 h at room temperature. For the development of peroxidase activity, 0.05% diaminobenzidinetetrahydrochloride (Sigma-Aldrich; Merck KGaA) was used for 10 min at room temperature. Sections were counterstained with hematoxylin for 20 sec and viewed under an inverted phase microscope (IX80 microscopy; Olympus Corporation) and analyzed using Image Pro Insight 6.0 (Media Cybernetics, Inc., Rockville, MD, USA).
Electron microscopy. Within 1-2 min following isolation, lung tissues were sliced (~1 mm thick) on ice, fixed with 2.5% (v/v) glutaraldehyde for 30 min at 4˚C, postfixed with 1% (v/v) osmic acid for 1 h at 4˚C, and were dehydrated and embedded with Epon812 at 40˚C for 4 h, 50˚C for 2 h, and 90˚C for 12 h. Thinner sections (0.5-1 µm) were sliced, stained with 0.5% (w/v) toluidine blue, and viewed under a Nikon Eclipse Ci-E microscope (Nikon Corporation, Tokyo, Japan). Ultrathin sections (~60 nm) were cut, double-stained with 2.0% (w/v) uranyl acetate for 20 min and 2.0% (w/v) lead citrate for 15 min at room temperature, and viewed under a transmission electron microscope (HITACHI HT7700; Hitachi Ltd., Tokyo, Japan).
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.
To obtain evidence of apoptosis in lung cells, TUNEL assay was performed according to the manufacturer's protocol (Roche Molecular Diagnostics, Pleasanton, CA, USA). Briefly, slices of lung tissues (4-5 µm) were embedded in paraffin. Cells were counted based on positive nuclei staining from five microscopic fields (magnification, x200) under a light microscope (Olympus Corporation) by an experienced pathologist. The apoptotic index of each experimental group was expressed as the ratio of the number of apoptotic cells to the total number of lung cells.
Statistical analysis. Data were expressed as the mean ± standard deviation. Comparisons between groups were made using one-way analysis of variance with Bonferroni correction for post hoc comparison. Continuous variables were fixed to normal distribution by Kolmogorov-Smirnov test and equal variances by the homogeneity of variance test. Pearson's correlation coefficient was used to determine correlations between the ratios of ACE2/ACE, Bax, cleaved caspase-3, and Bcl-2 and the ratio of Bcl-2/Bax. P<0.05 was considered to indicate a statistically significant difference.
Results
Histological analysis of the APE-CA lung. Histological analysis of the control animals demonstrated regular bronchiolar and alveolar walls, with no congestion in the alveolus (Fig. 1A and B) , whereas APE-CA animals had damaged bronchiolar and alveolar walls and mildly congestive alveolar space (Fig. 1C and D) . For the ROSC-SA group, histological analysis demonstrated increased alveolar space congestion (Fig. 1E   Figure 1 . Histological analysis of pulmonary damage in the following experimental animal groups: Control (A) magnification, x100 and (B) x400; acute pulmonary embolism-cardiac arrest group (C) magnification, x100 and (D) x400; ROSC-saline group (E) magnification, x100 and (F) x400; and ROSC-captopril group (G) magnification, x100 and (H) x400. Black arrows indicate the alveolar space between cells. ROSC, return of spontaneous circulation.
and F) with a large number of exudative cells and pulmonary interstitial edema. However, captopril treatment alleviated the alveolar space congestion following ROSC ( Fig. 1G and H) .
ACE2/ACE imbalance in the APE-CA group.
The expression of ACE, AT1, ACE2, and Mas proteins in porcine lung tissues was measured by western blotting in the CA and ROSC groups following induction of APE ( Fig. 2A-C) . As depicted in Fig. 2C , the levels of ACE and AT1 (ACE, 0.24±0.02 to 0.48±0.03; AT1, 0.27±0.01 to 0.69±0.02) in the CA group were significantly higher than those of the control group (P<0.001), but lower in the ROSC-SA (0.31±0.14 and 0.33±0.09) compared with the CA group (P<0.05). The ACE2/ACE ratio declined sharply in CA (from 1.61±0.03 to 0.72±0.04) following induction of APE. Notably, the protein levels of Mas receptor were decreased in the ROSC-SA group following induction of APE (0.19±0.04) compared with the APE-CA group (0.30±0.01) (Fig. 2C) . The expression of AT1 receptor increased, but ACE2 and Mas receptor expression levels were unchanged in the ROSC-Cap compared with the ROSC-SA group.
Ultrastructural changes in lung cells. Pulmonary endothelial cell apoptosis and endothelial matrix proliferation in the APE-CA and ROSC-SA groups are illustrated in Fig. 3A and B. Electron microscopy demonstrated loose connections between endothelial cells, extensive nuclear shrinkage, chromatin condensation and margination, cytoplasmic vacuoles (Fig. 3C) , as well as type II pneumocyte with lamellar body swelling and partial desquamation, in the APE-CA group (Fig. 3D) .
Pulmonary apoptosis and the effect of captopril on the APE-CA group.
To measure pulmonary apoptosis, the expression of Bax, Bcl-2, cleaved caspase-3 ( Fig. 2A ) and caspase-3 ( Fig. 2B) proteins in the lung tissues was evaluated by western blot analysis. The pro-apoptotic protein Bax was higher in the pulmonary tissue of the APE-CA and ROSC-SA groups following induction of APE compared with the control group (P<0.05; Fig. 2D ). However, Bax protein levels were lower in the ROSC-SA group than in the APE-CA group (P<0.05). Compared with the control group, although the expression of anti-apoptotic protein Bcl-2 (and the Bcl-2/Bax ratio) were lower in the APE-CA group (P<0.001), these returned to normal levels during ROSC following APE. Cleaved caspase-3 or cleaved caspase-3/caspase-3 ratio was upregulated in the CA and ROSC-SA groups compared with the control group (P<0.001; Fig. 2D ). Captopril treatment inhibited pulmonary cleaved caspase-3 expression and promoted Bcl-2 expression compared with the saline administration following ROSC ( Fig. 2A, D) . The expression of cleaved caspase-3 was analyzed by conventional immunohistochemistry. Cleaved caspase-3 expression was not detected in the control group (Fig. 4A ) but was markedly observable in the nucleus and cytoplasm of pulmonary epithelial cells of the APE-CA and ROSC groups (Fig. 4B-E) . Additionally, captopril reduced cleaved caspase-3 staining in lung epithelial cells following ROSC ( Fig. 4D and E) . Furthermore, based on the results of TUNEL assay, the apoptotic index in APE-CA and ROSC-SA groups increased compared with the control group, and after ROSC, captopril treatment partially attenuated pulmonary apoptotic index (Fig. 5) . Correlation between ACE2/ACE and apoptotic factors during an APE. A negative correlation between ACE2/ACE ratio and Bax (r=-0.772, P<0.01) was detected. The protein levels between ACE2/ACE ratio and cleaved caspase-3 were negative correlative factors (r=-0.689, P<0.05) and the Bcl-2 (r=0.559, P<0.05) and Bcl-2/Bax ratio (r=0.716, P<0.01) were positive correlative factors of ACE2/ACE ratio (Fig. 6 ).
Discussion
Pneumocyte apoptosis is the most significant pathological observation in the lung tissue following an APE. The association between ACE2/ACE axis and the pathological changes in the lung during ischemia and reperfusion induced by massive APE has not been established. The present study aimed to investigate this association by inducing CA (ischemia) and ROSC (reperfusion) in an APE pig model. The present study observed congested alveolar space and apoptosis in endothelial cells, which may be due to the loss of ACE2/ACE balance in the lung tissue and reduced ACE2/ACE ratio. The apoptosis in lung tissue was aggravated at the APE-CA group, but was attenuated following ROSC. Following captopril treatment, apoptosis in the lung tissue was alleviated. Thus, it can be concluded that the ACE2/ACE balance may be positively correlated with the expression of anti-apoptotic factors during APE-induced lung injury in the pig model.
Apoptosis is the main mechanism of histological pulmonary injury in APE-CA (3). Deng et al (14) established a canine model of pulmonary thromboembolism by selectively embolizing blood clots to the right lower lobar pulmonary artery. After 2 weeks, embolectomy of the reperfusion and ischemia groups revealed similar pulmonary pathology to the present study, including collapsed alveolar structures and the presence of few exudative cells in the alveolar space in the ischemia group (comparable to the APE-CA group) and a large number of exudative cells and exudation within the alveolar spaces in the reperfusion group (comparable to the ROSC groups). In the present study, higher congestion in the alveolar spaces was present in the ROSC group compared with the APE-CA group. However, captopril treatment inhibited alveolar congestion. Electron microscopy visualization revealed apoptosis in pulmonary endothelial cells and type II pneumocytes with lamellar bodies partially desquamated in the APE-CA model. Thus, alveolar congestion may have been caused by injury to the alveolar epithelial barriers resulting from pulmonary endothelial cell apoptosis.
The role of apoptosis in the pathogenesis of interstitial pulmonary fibrosis, acute respiratory distress syndrome, and chronic obstructive pulmonary disease has been described previously (15) (16) (17) (18) . Recent studies suggested that apoptosis serves an important role in chronic pulmonary embolism (19) (20) (21) (22) . In a mouse model of chronic pulmonary thromboembolism, lung parenchyma had markedly elevated levels of proliferating cells and apoptotic cells, and activity of pro-apoptotic caspase-3 compared with normal lungs (19) . Mercier et al (20) investigated vessel alterations induced by high flow through the creation of an aortopulmonary shunt and reported increased smooth muscle cell proliferation, but following 1 week of shunt closure, smooth muscle cells demonstrated increased apoptosis without proliferation. Dolkart et al (21) reported that the rate of apoptosis in the bronchoalveolar lavage peaks at 12 and 48 h following ischemia-reperfusion. When investigating the mechanisms associated with lung ischemia-reperfusion injury in pulmonary thromboembolism, Deng et al (22) demonstrated that the number of apoptotic pneumocytes had a negative correlation with the ratio of arterial oxygen partial pressure to fractional inspired oxygen, whereas it had a positive correlation with alveolar polymorphonuclear neutrophils in the reperfusion group. In the present study, APE-CA and ROSC groups had increased levels of the pro-apoptotic factors Bax and cleaved caspase-3, and inhibition of the anti-apoptotic factor Bcl-2 compared with the control group. Following ROSC, the reperfusion may have alleviated apoptosis in the lung cells as indicated by the reduction in Bax and the increase of Bcl-2 expression compared with the APE-CA group. Previous studies have reported that the classical ACE-AngII-AT1 axis of the renin-Ang system serves an important role in the apoptosis of AECs induced by either Fas activation, or chemically by antiarrhythmic agents benzofuran amiodarone (6) or fibrogenic agent bleomycin (7) . A study reported that an AT1 receptor blocker, losartan, reduced the protein levels of caspase-3 in lipopolysaccharide (LPS)-induced lung injury (23) . Additionally, evidence of inhibition of pneumocyte apoptosis via activation of ACE2/Ang-(1-7)/Mas axis has been reported. Yang et al (24) proved that Ang-(1-7) treatment is effective in ameliorating Ang II-induced apoptosis in human umbilical vein endothelial cells. Li et al (25) illustrated that LPS induced apoptosis in pulmonary microvascular endothelial cells and reduced the ratio of ACE2/ACE, while ACE2 treatment alleviated LPS-induced apoptosis by reversing the ACE2/ACE imbalance and increasing Ang-(1-7) levels. Other studies have demonstrated that the ACE2/ACE imbalance is an important pathological mechanism not only in LPS-induced acute lung injury but also in many diseases such as in spontaneous hypertension (26) , acute pancreatitis (27, 28) , hepatic fibrogenesis (29) , and in renal injury (30) . In agreement with these studies, the present reported that there was a positive correlation between ACE2/ACE ratio and anti-apoptotic factors in APE-CA pigs, suggesting that restoring the ACE2/ACE balance may be a therapeutic strategy for resolving pneumonocyte apoptosis.
Captopril treatment has been widely investigated in several studies on pulmonary and cardiac diseases. Fan et al (31) demonstrated that captopril treatment resulted in lower expression of ACE and AT1 receptors and higher expression of ACE2 and AT2 receptors in mouse Lewis lung carcinoma cells under hypoxia conditions. Li et al (32) in an in vivo study using rat pulmonary microvascular endothelial cells demonstrated that captopril pretreatment significantly reversed the LPS-induced pathophysiological changes in the lung, reduced the ratio of Ang II to Ang-(1-7), and restored the ACE/ACE2 ratio to normal levels. Our previous study demonstrated that captopril treatment lowered post-resuscitation pulmonary vascular resistance in pulmonary embolism by activating the serum ACE2/Ang-(1-7)/Mas axis (10) . In the present study, the anti-apoptotic action of captopril in lung epithelial cells following ROSC was demonstrated by increased Bcl-2 protein levels, as assessed by western blot analysis and decreased cleaved caspase-3 protein levels, as assessed by immunohistochemical analysis. In addition, the TUNEL assay showed that the apoptotic index was decreased following captopril treatment.
However, the present study has some limitations. Firstly, although the porcine model is expected to simulate the human model of APE-CA injury, the results may be hindered by species and organ-dependent differences. Additionally, the present experiments did not measure lung injury biomarkers in parallel, and thus the correlation between ACE2/ACE axis and lung injury could not be validated. Therefore, the molecular signaling pathway(s) mediating the effects of the ACE2 axis on post-resuscitation lung apoptosis in APE require further investigation.
In conclusion, the present study confirmed that a loss of ACE2/ACE balance may be a key mechanism of pathogenesis in APE-CA. Levels of apoptotic proteins were elevated in APE-CA animals, but this effect was reversed following ROSC. Treatment with captopril had anti-apoptotic effects in the lung tissue following ROSC. Taken together, Figure 6 . Correlation between protein levels of ACE2/ACE and apoptotic factors during an APE. ACE, angiotensin-converting enzyme; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-associated X protein.
the present study indicated that restoring the ACE/ACE2 balance may be an important therapeutic strategy in the management of APE-CA.
